| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-1-4939-9773-2_2 |
| P698 | PubMed publication ID | 31502146 |
| P2093 | author name string | Hassane M Zarour | |
| Diwakar Davar | |||
| P2860 | cites work | B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells | Q24291070 |
| LAG-3, a novel lymphocyte activation gene closely related to CD4 | Q24300309 | ||
| Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily | Q24306525 | ||
| The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function | Q24307921 | ||
| Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation | Q24311763 | ||
| The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells | Q24314985 | ||
| Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway | Q24532119 | ||
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 | ||
| Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients | Q24598792 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity | Q24651041 | ||
| Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens | Q24675169 | ||
| Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation | Q24676080 | ||
| PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells | Q24677367 | ||
| CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 | ||
| BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection | Q27303620 | ||
| T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface | Q27644083 | ||
| T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells | Q27659032 | ||
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | Q27853339 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| CEACAM1 regulates TIM-3-mediated tolerance and exhaustion | Q28115443 | ||
| Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 | Q28116224 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 | Q28137860 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family | Q28207890 | ||
| Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A | Q28216798 | ||
| CTLA-4 can function as a negative regulator of T cell activation | Q28235866 | ||
| A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9 | Q28270715 | ||
| Lack of TIM-3 immunoregulation in multiple sclerosis | Q28273324 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity | Q28281686 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| Molecular basis of T cell inactivation by CTLA-4 | Q28291723 | ||
| A new member of the immunoglobulin superfamily--CTLA-4 | Q28299244 | ||
| B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator | Q28506619 | ||
| Src kinases Fyn and Lck facilitate the accumulation of phosphorylated CTLA-4 and its association with PI-3 kinase in intracellular compartments of T-cells | Q43776772 | ||
| T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. | Q44384732 | ||
| Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma | Q45287769 | ||
| B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells | Q45304842 | ||
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations | Q46555595 | ||
| Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. | Q47199905 | ||
| Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases | Q47722514 | ||
| Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade | Q47958949 | ||
| The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation | Q48156081 | ||
| Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses | Q48186068 | ||
| BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints | Q48530138 | ||
| TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer | Q50116964 | ||
| Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. | Q50935715 | ||
| CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. | Q52714314 | ||
| Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. | Q52721686 | ||
| Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. | Q55421471 | ||
| Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients | Q56888845 | ||
| Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens | Q56891909 | ||
| Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation | Q56899423 | ||
| Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation | Q56901389 | ||
| Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo | Q56901901 | ||
| CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism | Q56906680 | ||
| Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement | Q56908957 | ||
| Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4 | Q56908993 | ||
| High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3 | Q59799577 | ||
| Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy | Q61997045 | ||
| Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes | Q63408418 | ||
| Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site | Q67969096 | ||
| Cancer Tumor antigens | Q74076460 | ||
| Fibrinogen‑like‑protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis | Q88912522 | ||
| CD226 opposes TIGIT to disrupt Tregs in melanoma | Q90474664 | ||
| Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 | Q90726576 | ||
| Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells | Q91009159 | ||
| Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition | Q34507394 | ||
| Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. | Q34509694 | ||
| A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling | Q34516242 | ||
| Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. | Q34590849 | ||
| PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients | Q34606735 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma | Q34647109 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC | Q34938832 | ||
| LAG-3 regulates plasmacytoid dendritic cell homeostasis | Q34939924 | ||
| Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo | Q35235365 | ||
| PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation | Q35311785 | ||
| Metalloproteases regulate T-cell proliferation and effector function via LAG-3 | Q35612460 | ||
| Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. | Q35669414 | ||
| Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors | Q35740366 | ||
| PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs | Q35771948 | ||
| CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. | Q35783166 | ||
| Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation | Q35842036 | ||
| Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy | Q35920288 | ||
| BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties | Q36060241 | ||
| TIGIT predominantly regulates the immune response via regulatory T cells. | Q36266506 | ||
| CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. | Q36284594 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| Vstm3 is a member of the CD28 family and an important modulator of T-cell function | Q28512622 | ||
| Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3 | Q28594769 | ||
| Cutting edge: TIGIT has T cell-intrinsic inhibitory functions | Q28594957 | ||
| Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 | Q29619280 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| T cell exhaustion | Q29620463 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. | Q30515733 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Identification of CD112R as a novel checkpoint for human T cells | Q33289401 | ||
| Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma | Q33386521 | ||
| Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer | Q33606107 | ||
| T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. | Q33658811 | ||
| T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling | Q33792958 | ||
| VISTA Regulates the Development of Protective Antitumor Immunity | Q33978040 | ||
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice | Q33996674 | ||
| Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection | Q34093225 | ||
| Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease | Q34112417 | ||
| Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). | Q34147524 | ||
| Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity | Q34161493 | ||
| Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients | Q34161579 | ||
| TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression | Q34170158 | ||
| The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells | Q34187872 | ||
| Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells | Q34195216 | ||
| Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand | Q34290833 | ||
| Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity | Q34364103 | ||
| VISTA is an immune checkpoint molecule for human T cells | Q34413221 | ||
| Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells | Q34428196 | ||
| Genomic organization of the human LAG-3/CD4 locus | Q34447718 | ||
| Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex | Q34451878 | ||
| Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. | Q34462234 | ||
| TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients | Q34471375 | ||
| CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. | Q34476027 | ||
| Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. | Q36377233 | ||
| A molecular perspective of CTLA-4 function | Q36427322 | ||
| Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding | Q36520103 | ||
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
| Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells | Q36603122 | ||
| A crucial role for HVEM and BTLA in preventing intestinal inflammation | Q36699814 | ||
| PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis | Q36750008 | ||
| CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion | Q36835173 | ||
| CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients | Q36937124 | ||
| Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection | Q36979967 | ||
| The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 | ||
| Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues | Q37115223 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines | Q37406010 | ||
| Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. | Q37426386 | ||
| Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients | Q37513109 | ||
| TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer | Q37629557 | ||
| Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy | Q37630991 | ||
| Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma | Q37677908 | ||
| PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors | Q37726682 | ||
| PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines | Q38264346 | ||
| SHP2 sails from physiology to pathology. | Q38580957 | ||
| Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. | Q38630528 | ||
| IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | Q38709131 | ||
| Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy | Q38743794 | ||
| Reversing T-cell Dysfunction and Exhaustion in Cancer | Q38809776 | ||
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
| Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis | Q40216414 | ||
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. | Q40248504 | ||
| CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells | Q40266751 | ||
| BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma. | Q40357836 | ||
| The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. | Q40850973 | ||
| CTLA-4 and Autoimmunity: New Twists in the Tale | Q40899285 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation | Q40957673 | ||
| The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase | Q41469848 | ||
| Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice | Q41514824 | ||
| CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization | Q41591286 | ||
| The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms | Q41834044 | ||
| Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. | Q41909802 | ||
| Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors | Q42051381 | ||
| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells | Q43448621 | ||
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 23-60 | |
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | Methods in Molecular Biology | Q15752859 |
| P1476 | title | Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors | |
| P478 | volume | 2055 |
Search more.